As shown in Figure 1, compared with control treatments, there was no significant increase of risk of grade 1–5 pancreatitis in the CTLA-4 inhibitor subgroup (versus chemotherapy/placebo, RR 1.81, 95% CI: 0.82–4.03, p = 0.143) and in the PD-1 inhibitor subgroup (versus chemotherapy, RR = 0.93, 95% CI: 0.16–5.33, p = 0.937). This evidence concerns the gene CTLA4 and pancreatitis.